Actively Recruiting
AI-Enhanced Optimization of Acute Levodopa Challenge Test
Led by Beijing Tiantan Hospital · Updated on 2025-04-29
2000
Participants Needed
1
Research Sites
135 weeks
Total Duration
On this page
Sponsors
B
Beijing Tiantan Hospital
Lead Sponsor
R
Ruijin Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
A quantitative evaluation method was developed for Parkinson's disease and other atypical parkinonism by integrating an innovative motor paradigm with perception technologies and artificial intelligence. Combined with traditional motor paradigms and the acute levodopa challenge test, this study aims to identify diagnostic cut-off values for PD and other atypical parkinonism, explore digital biomarkers for early and differential diagnosis, and establish a corresponding diagnostic model.
CONDITIONS
Official Title
AI-Enhanced Optimization of Acute Levodopa Challenge Test
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients aged 50 to 75 years, all genders
- Confirmed Parkinson's disease diagnosed by 2015 International Movement Disorder Society criteria, with Hoehn-Yahr score 64 2.5 for early stage or 2.5-5 for intermediate/advanced stages
- Confirmed or probable multiple system atrophy diagnosed by 2022 International Movement Disorder Society criteria
- Confirmed or probable progressive supranuclear palsy diagnosed by 2017 International Movement Disorder Association PSP Collaborative Group criteria
- Diagnosed vascular parkinsonism according to 2004 International Association for Movement Disorders and 2017 Chinese expert consensus
- Drug-induced parkinsonism with reversible symptoms related to specific drugs and other causes ruled out
- Probable or probable corticobasal degeneration based on 2019 Chinese diagnostic criteria
- Probable or possible dementia with Lewy bodies diagnosed by 2017 international and 2021 Chinese diagnostic criteria, exhibiting parkinsonism
- Ability and willingness to undergo study assessments and sign informed consent
You will not qualify if you...
- Cognitive dysfunction with MMSE score less than 23 preventing study completion
- Inability to tolerate levodopa challenge test
- Failure of major organs such as heart, lung, liver, kidney, or presence of malignant tumors or unstable serious diseases
- Serious behavioral problems or mental disorders
- Inability to sign informed consent
- Other conditions judged by the investigator as unsuitable for participation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Beijing Tiantan Hospital, Affiliated to Capital Medical University
Beijing, China, 100070
Actively Recruiting
Research Team
T
Tao Feng, MD
CONTACT
L
Lingyan Ma, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
7
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here